ANVS News and Press, Annovis Bio Inc. From 02/12/24

2024-02-12 09:06:20 ET Summary A small sample of patient anecdotes on the internet suggest that buntanetap has some degree of underlying activity in Parkinson’s disease (PD). 24-38% of patient anecdotes report a noticeable/measurable improvement in Parkinson’s sympto...

2024-02-01 16:10:53 ET More on Annovis Bio Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials Ann...

MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neur...

2024-01-29 23:44:21 ET Summary Annovis will likely announce results from it Parkinson's disease and Alzheimer's disease trials in the next couple of month. Annovis inhibits the formation of the amyloid precursor protein. The primary triggers for Alzheimer's disease are unrelat...

2024-01-24 12:48:28 ET More on Mid-day movers $ stocks. Peraso Inc. (PRSO) Q3 2023 Earnings Call Transcript Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript Sight Sciences says Q4 total revenue i...

2024-01-24 11:30:45 ET More on Annovis Bio Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials Annovis Bio gains after enrollment update on trial for Alzheimer...

2024-01-24 10:01:06 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

2024-01-24 08:40:30 ET Losers: Theratechnologies THTX -30% says FDA rejected new Egrifta version . Annovis Bio ( ANVS ) -11% refines timeline for Parkinson’s phase III study data announcement . BlackBerry Ltd BB -11% announces proposed private ...

MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postponement in the Phase III study data release for buntanetap in Parkinson’s Disease. This adj...

2024-01-20 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings r...